FTC targets Novo's Ozempic, others in crackdown on 300-plus 'junk' patent listings in FDA database
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. After an initial round of challenges launched in November against more than 100 patents by nine drugmakers, the FTC is back …